Verrica reports record Q3 revenue and common warts milestones
Verrica achieved record U.S. YCANTH revenue of $5.7 million, extended its cash runway, and secured access to additional non-dilutive funding ahead of pivotal common warts trial data.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed